Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorecivivint
- Development stage
- Phase 3
- Lead developer
- Biosplice Therapeutics
- Modality
- Small Molecules
- Administration
- Intraarticular
01
Overview
Lorecivivint is a small molecule investigational drug developed as a potential disease-modifying osteoarthritis drug (DMOAD), primarily for knee osteoarthritis. It acts as an intra-articular inhibitor of CDC-like kinase 2 (CLK2) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), modulating the Wnt signaling pathway. By inhibiting these intranuclear kinases, lorecivivint improves chondrocyte health and function while reducing inflammation. Preclinical and clinical studies have shown that it preserves cartilage structure, increases joint space width, reduces pain and improves function in patients with moderate to severe knee osteoarthritis. Phase 3 trials are ongoing to further evaluate its long-term efficacy and safety[1][3][4][5][6][7]. Developers: Biosplice
- Other names
- adavivint
02
Targets
CLK2 (CDC-like kinase 2)DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)
Beyond the preview
Go deeper on lorecivivint.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorecivivint.